Well summarised. They have already checked the chemistry out of co-formulations in the lab and no issues. Megan Baldwin sees Opt-302 potentially being approved as an “add on label” to all vegF-A inhibitors. Also looks like we won’t have readout on DME trial until June but a good result will IMO definitely up the value ante of the company because as Megan explains in the webcast the trial design has specifically focussed on patients that have reached the end of the line with VegF-À drug therapy
Ann: Opthea to Present at SVB Leerink Healthcare Conference, page-13
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
89.5¢ |
Change
-0.015(1.65%) |
Mkt cap ! $1.101B | |||
| Open | High | Low | Value | Volume |
| 91.0¢ | 92.0¢ | 87.5¢ | $1.496M | 1.676M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1705 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.5¢ | 46363 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |